Treats insomnia characterized. ANDA 202761, held by Zydus Lifesciences. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 202761 (Doxepin Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Aug 16, 2023, with 0 approved supplements and 0 published complete response letters.
Doxepin tablets are indicated for the treatment of insomnia characterized by difficulties with sleep maintenance. ( 1, 14 )
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2023 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 3MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 6MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters